Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial

BACKGROUND: The primary analysis of the INBUILD trial showed that in subjects with progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in forced vital capacity (FVC) over 52 weeks. We report the effects of nintedanib on ILD progression over the whole trial. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Flaherty, Kevin R., Wells, Athol U., Cottin, Vincent, Devaraj, Anand, Inoue, Yoshikazu, Richeldi, Luca, Walsh, Simon L.F., Kolb, Martin, Koschel, Dirk, Moua, Teng, Stowasser, Susanne, Goeldner, Rainer-Georg, Schlenker-Herceg, Rozsa, Brown, Kevin K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927709/
https://www.ncbi.nlm.nih.gov/pubmed/34475231
http://dx.doi.org/10.1183/13993003.04538-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927709/
https://www.ncbi.nlm.nih.gov/pubmed/34475231
http://dx.doi.org/10.1183/13993003.04538-2020

Ejemplares similares